Literature DB >> 1486050

Plasma cell leukaemia with alpha-interferon therapy in myeloma.

M Sawamura, K Murayama, G Ui, T Matsushima, J Tamura, H Murakami, T Naruse, J Tsuchiya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1486050     DOI： 10.1111/j.1365-2141.1992.tb06484.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

Review 1.  Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?

Authors:  J Bladé; J Esteve
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

2.  Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.

Authors:  D F Jelinek; K M Aagaard-Tillery; B K Arendt; T Arora; R C Tschumper; J J Westendorf
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

3.  A role for IFN-lambda1 in multiple myeloma B cell growth.

Authors:  A J Novak; D M Grote; S C Ziesmer; V Rajkumar; S E Doyle; S M Ansell
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

Review 4.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

5.  Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNalpha.

Authors:  Lun Song; Yan Li; Beifen Shen
Journal:  Cancer Cell Int       Date:  2002-07-08       Impact factor: 5.722
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.